Goldman Sachs has reinstated its coverage of Medtronic (MDT), resuming analyst evaluation of the medical technology company.

An analysis explores whether Medtronic can effectively challenge Intuitive Surgical's long-standing dominance in the market for robotic surgical systems.

Medtronic's stock appears to have bottomed out, with analysts anticipating a healthy rebound ahead.

Medtronic (MDT) stock has risen by 5.7% following a stellar performance in its fourth quarter. The positive Q4 results have contributed to the company's stock growth.

Medtronic's stock saw a notable increase today, though the specific reasons for the pop were not immediately detailed.

Greif has announced a 10.7% increase in its dividend to $0.93, while Medtronic plc has raised its dividend by 1.4% to $0.72. These increases reflect positive financial performance and a commitment to shareholder returns from both companies.

Medtronic's cardiovascular and diabetes segments continued their strong performance in the fourth quarter, extending double-digit growth streaks.

An analysis questions whether Medtronic stock is underperforming compared to the Nasdaq index.

This report highlights the leading Wall Street analyst research calls for Thursday, covering companies such as DraftKings, ETSY, GE Healthcare, and more.

Medical technology company Medtronic is set to acquire SPR Therapeutics in a deal valued at around $650 million. The acquisition will expand Medtronic's portfolio in the healthcare sector.

Previews indicate that Medtronic and Donaldson Company are both expected to continue their long-standing dividend growth streaks. Medtronic anticipates extending its streak to 47 years, while Donaldson Company is set to reach 30 years of consecutive dividend increases.

Medtronic (MDT) emphasized the strong momentum of its Affera platform and its recent FDA Breakthrough Device Designation, signaling advancements in its medical technology.

Medical technology company Medtronic has announced that its IT network was subjected to a cyberattack. The company confirmed that despite the incident, its operations have not been disrupted.

Truist has reduced its price target for Medtronic, even as it anticipates a stable performance for the company in the first quarter.

Citi has cut its target for Medtronic (MDT), while Stifel has lowered its outlook for the company, following the recent MiniMed IPO.

Medtronic has been cleared to market its new robotic surgical system designed for cranial procedures, expanding its presence in advanced medical technology.

Medtronic has announced that its OmniaSecure product has received FDA approval for an expanded indication, broadening its use in medical applications.

Medtronic (MDT) has declared a quarterly dividend of $0.71 per share, providing shareholders with a regular payout.

MiniMed, a subsidiary of Medtronic, has priced its initial public offering of $560 million at $20 per share.

An article provides an investment analysis for Medtronic, suggesting it as a potential lifetime hold for medical device stocks.

Medtronic's diabetes unit, MiniMed, is reportedly seeking a valuation of $7.9 billion as it prepares for a US initial public offering.

Medtronic is set to cut 81 employees at its California diabetes site, impacting its workforce in the region.

Medtronic reported a decrease in profit despite an increase in revenue, suggesting that rising costs or other factors impacted its profitability.

Medtronic reported a decrease in profit despite achieving higher revenue, suggesting increased operational costs or other financial pressures.

Medtronic reported a decrease in profit even though the company experienced an increase in revenue.

Wednesday's top Wall Street analyst research calls include Cadence Design, Crox, Genuine Parts, Kratos Defense, Medtronic, Palantir, StubHub, Transocean, and more.

Genuine Parts shares fell sharply after the company reported a significant earnings miss, overshadowing its announced plans for a breakup.

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic's cardiovascular and diabetes divisions posted mid-teens growth in the third fiscal quarter, indicating strong performance in these key areas.

Medtronic has successfully completed its first Hugo robotic-assisted surgery in the United States, marking a significant milestone for the company's surgical robotics platform.

Medtronic stock may have emerged as the best buying opportunity within the entire healthcare sector, according to market analysis.

This article highlights significant healthcare news from the past week, focusing on companies such as UnitedHealth, Medtronic, and Eli Lilly.

Leading Wall Street analysts have issued their significant stock recommendations for Thursday, covering major companies such as Nvidia, Apple, Broadcom, and Netflix. These calls provide insights into potential market movements and investment opportunities.

Medtronic received an upgrade from BTIG after reporting better-than-expected financial results for its fiscal year 2026 fourth quarter. The upgrade reflects positive analyst sentiment regarding the company's performance.

Medtronic is actively pursuing acquisitions as a core strategy to drive its growth, indicating a belief that strategic purchases will expand its market presence and capabilities.

Medtronic announced a significant increase in its fourth-quarter revenue, reporting nearly double-digit growth for the period.

Several companies, including IDT Corporation, ChargePoint Holdings, Medtronic, and CrowdStrike, are preparing to release their quarterly earnings reports. Investors are anticipating what to expect from their Q3 2026, Q1 2027, Q4, and Q1 earnings, respectively.

Medtronic faces the challenge of accelerating its growth to catch up with its larger and faster-growing rivals in the medical technology sector.

Medtronic has announced plans to establish a new European Software Development Hub in Galway, which is expected to create over 80 jobs. This investment will bolster the company's software capabilities and contribute to local employment.

Medtronic Announces Intent To Acquire Spr Therapeutics  TradingView

Medtronic has announced that its Stealth AXiS System has received the CE Mark, following its earlier approval by the FDA, expanding its market access.

Medtronic plc (MDT) has announced that its Stealth AXiS™ Surgical System has received the CE Mark, allowing its commercialization in the European market.

Medtronic has successfully concluded its acquisition of CathWorks for $585 million. This strategic move aims to expand Medtronic's portfolio in the medical technology sector.

Mizuho has lowered its target price for Medtronic (MDT) ahead of the company's first-quarter earnings report. Despite the adjustment, Mizuho maintains a positive view on the stock.

Stifel has lowered its price target for Medtronic (MDT) to $95, attributing the adjustment to the anticipated effects of the MiniMed IPO.

This article highlights notable healthcare headlines for the week, focusing on developments related to companies such as Merck, Medtronic, and Novartis.

Medtronic (MDT) has announced an expanded partnership with Merit Medical, focusing on the ViaVerte System.

Medtronic has acquired Scientia Vascular, a move aimed at strengthening its neurovascular platform and expanding its medical device offerings.

Medtronic has announced its intention to acquire Scientia Vascular for $550 million, aiming to strengthen its neurovascular business and expand its medical device portfolio.

Medtronic Unit Raises $560 Million in US IPO Priced Below Range  Bloomberg

Medtronic's diabetes business unit, MiniMed, is reportedly planning an Initial Public Offering (IPO) in the United States, aiming to raise $784 million.

Medtronic's diabetes unit, MiniMed, is reportedly seeking to raise up to $784 million through an initial public offering (IPO) in the U.S. market.

Dividend-paying medtech giant Medtronic is highlighted as a company built to survive any market crash, suggesting its resilience in volatile economic conditions.

Medtronic reported a decrease in profit even with an increase in revenue, suggesting higher expenses or other financial pressures.

Medtronic reported a decrease in profit even though its revenue increased.

Medtronic reported a decrease in profit even though its revenue increased.

Medtronic reported a decrease in profit even with an increase in revenue, suggesting that rising costs or other factors are impacting its bottom line.

Medtronic announced its third-quarter 2026 revenues reached $9 billion, attributed to robust demand for its Pulsed Field Ablation (PFA) technology.

A summary of Medtronic plc's Q3 2026 earnings call provides key insights into the company's financial performance and future outlook.

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic reported a decrease in profit even as the company experienced higher revenue.

Medtronic reported a decrease in profit even as the company experienced an increase in revenue.

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic reported a decrease in profit even as the company experienced higher revenue.

Medtronic reported better-than-expected quarterly profits, driven by robust demand for its heart-related medical devices.

Medtronic plc (MDT) has acquired SPR Therapeutics, a move aimed at enhancing its prospects and offerings in the pain intervention sector.

An analysis provides guidance on how to potentially earn $500 a month from Medtronic stock following its Q4 earnings report.

BTIG analysts suggest that Medtronic's shares are currently trading at a discount compared to its competitors, making it an opportune time for investment.

Medtronic projects organic revenue growth of 6.75%-7.25% for fiscal year 2027, with an estimated EPS of $5.90-$6.00, despite a $250 million impact from tariffs. The company also reported its strongest annual revenue growth in a decade.

Medtronic announced its Q4 earnings, reporting a non-GAAP EPS of $1.55 and revenue of $9.81 billion, both beating analyst estimates. However, the company's FY26 EPS outlook fell below consensus expectations.

Medtronic reported a strong fourth-quarter beat, with its cardiovascular and diabetes segments continuing their double-digit growth streaks. The company's performance was notably boosted by its cardiovascular division.

Medtronic plc (MDT) has announced its intention to acquire SPR Therapeutics (SPR), a move that will expand its portfolio in the medical device sector.

Medtronic has announced its intention to acquire SPR, a developer of pain therapy, for $650 million. This acquisition aims to expand Medtronic's offerings in the pain management sector.

Medical technology companies Medtronic and BD have both named new leaders to key positions within their organizations.

An analysis of Medtronic's stock outlook explores whether Wall Street analysts are predominantly bullish or bearish on the company's future performance.

UBS and Jefferies have lowered their outlooks on Medtronic (MDT) following changes within the company's diabetes unit.

Pulnovo, a medical technology company, has successfully closed a $100 million financing round, which notably includes a strategic investment from Medtronic, bolstering its capital for future development and expansion.

Medtronic plc (MDT) is highlighted for its innovation pipeline and structural changes, which are seen as positive indicators for its stock performance.

A market digest has been released, providing an overview of several key companies including Markel Group Inc., Entergy, FedEx, Gap, Medtronic, Roche Holding AG, and Cleveland-Cliffs.

Jim Cramer expresses approval of Medtronic (MDT)'s recent corporate decisions and activities.

Medtronic has revised its earnings outlook for 2026 downwards, attributing the change to recent updates concerning its MiniMed products.

Medtronic plc has released its fourth-quarter financial results, reporting a GAAP EPS of -$1.11 and revenue of $33.48 million.

Medtronic's diabetes unit, MiniMed, experienced a decline in its stock value on its trading debut.

Medtronic's diabetes unit, MiniMed, is reportedly seeking $784 million in its upcoming US Initial Public Offering.

Medtronic plc (MDT) is reportedly gaining momentum through its diabetes and cardiovascular operations, indicating positive business performance in these sectors.

An article recommends Medtronic as the only healthcare stock to buy and hold indefinitely.

Medtronic reported a decrease in profit despite an increase in revenue.

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic reported a decrease in profit despite an increase in its overall revenue.

Medtronic has experienced a significant stock reversal, prompting analysis into its potential for further growth by 2026.

The key points and significant announcements from Medtronic's third-quarter earnings call have been summarized.

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

Medtronic Profit Falls Despite Higher Revenue  The Wall Street Journal

UBS has upgraded Southwest Airlines to 'buy,' citing untapped earnings potential from seating and bag fees.

IDEAYA Biosciences announced its GAAP EPS of -$0.94, beating estimates by $0.03, and reported revenue of $10.88 million, surpassing expectations by $4.93 million.